SCHEMBL14765197

SCHEMBL14765197

Cc1ccc2[nH]c(=O)c(C)nc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.56
MEN1 O00255 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
KMT2A Q03164 1/20 0.56
DAO P14920 2/20 0.50
DDO Q99489 1/20 0.46
CA12 O43570 1/20 0.46
CA9 Q16790 1/20 0.46
KDM4E B2RXH2 5/20 0.45
RAB9A P51151 1/20 0.45
CHEK1 O14757 2/20 0.43
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42
PARP1 P09874 1/20 0.42
PIM1 P11309 1/20 0.42
RPS6KA3 P51812 1/20 0.42
ALDH1A1 P00352 6/20 0.42
HPGD P15428 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14764938 0.85 PIN1 (0.56) MAPTCYP1A2CYP2C19KMT2ADAO
SCHEMBL14474327 0.82 CASP3 (0.45) MAPTMEN1CYP1A2CYP2C9CYP2C19
SCHEMBL14765152 0.82 BRD4 (0.53) DAOKDM4EBRD4
SCHEMBL6304037 0.82 HRH4 (0.56) MAPTMEN1CYP1A2KMT2ADAO
SCHEMBL22185868 0.80 KDM4E (0.64) MAPTMEN1CYP1A2CYP2C9CYP2C19
SCHEMBL30695515 0.80 ALDH1A1 (0.58) MAPTMEN1CYP1A2CYP2C19KMT2A
SCHEMBL707140 0.80 ALDH1A1 (0.58) MAPTMEN1CYP1A2CYP2C19KMT2A
SCHEMBL24427741 0.78 KDM4E (0.62) MAPTMEN1CYP1A2CYP2C9CYP2C19
SCHEMBL16938469 0.78 BRD4 (0.45) MAPTMEN1CYP1A2CYP2C9CYP2C19
SCHEMBL29778097 0.78 MAPT (0.50) MAPTMEN1CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3359154-B1 WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2021-05-26 EP disclosed
US-20200048223-A1 WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2020-02-13 US disclosed
WO-2017062688-A1 WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2017-04-13 WO disclosed
US-20140147386-A1 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2014-05-29 US disclosed
WO-2013034755-A1 TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS H. LUNDBECK A/S (DK) 2013-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048223-A1 WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF WNT1, WNT3A, CTNNB1 MAPT 3199/4885MEN1 4552/4885CYP1A2 2852/4885
US-20140147386-A1 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES PDE2A, PDE12, PDE5A MAPT 2788/4885MEN1 879/4885CYP1A2 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.